Tioga Pharmaceuticals Secures $18,000,000 New Funding Round

  • Feed Type
  • Date
    2/17/2010
  • Company Name
    Tioga Pharmaceuticals
  • Mailing Address
    9393 Towne Centre Dr. San Diego, CA 92121
  • Company Description
    Tioga Pharmaceuticals is engaged in the development of novel therapies for the treatment of gastrointestinal diseases. Tioga is developing asimadoline, a proprietary small molecule, for treating irritable bowel syndrome (IBS) and post operative ileus.
  • Website
    http://www.tiogapharma.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $18,000,000
  • Transaction Round
    Undisclosed
  • Proceeds Purposes
    The proceeds will be used to fund a Phase 3 clinical trial for asimadoline for the treatment of patients with diarrhea predominant Irritable Bowel Syndrome (D-IBS).
  • M&A Terms
  • Venture Investor
    Forward Ventures
  • Venture Investor
    New Leaf Venture Partners
  • Venture Investor
    BB Biotech Ventures
  • Venture Investor
    Genesys Capital

By posting a comment, you agree to our terms and conditions.